Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.


Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy, and modifications in lifestyle.

The Non-Small Cell Lung Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

Non-Small Cell Lung Cancer Pipeline Drugs Market Segmentation by Targets

Some of the targets in the Non-Small Cell Lung Cancer pipeline are Epidermal Growth Factor Receptor, Programmed Cell Death Protein, Programmed Cell Death 1 Ligand, Hepatocyte Growth Factor Receptor, GTPase KRas, and Tubulin among others. Epidermal Growth Factor Receptor was the largest target in the pipeline.

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Targets

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Targets

For more Non-Small Cell Lung Cancer pipeline drugs market target insights, download a free report sample

Non-Small Cell Lung Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the mechanisms of action in the Non-Small Cell Lung Cancer pipeline drugs market are Epidermal Growth Factor Receptor Inhibitor, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, Hepatocyte Growth Factor Receptor Inhibitor, and GTPase KRas Inhibitor among others. Epidermal Growth Factor Receptor Inhibitor was the leading MoA in the pipeline.

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Mechanisms of Action

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Mechanisms of Action

For more MoA insights into the Non-Small Cell Lung Cancer pipeline drugs market, download a free report sample

Non-Small Cell Lung Cancer Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Non-Small Cell Lung Cancer pipeline drugs market are intravenous, oral, subcutaneous, parenteral, intratumor, and intravenous drip among others. The majority of the pipeline drugs followed the oral route of administration.

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Routes of Administration

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Non-Small Cell Lung Cancer pipeline drugs market, download a free report sample

Non-Small Cell Lung Cancer Pipeline Drugs Market Segmentation by Molecule Types

The leading molecule types in the Non-Small Cell Lung Cancer pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, cell therapy, gene-modified cell therapy, and fusion protein among others. Small molecule was the leading molecule type in the pipeline.

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Molecule Types

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Non-Small Cell Lung Cancer pipeline drugs market, download a free report sample

Non-Small Cell Lung Cancer Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Non-Small Cell Lung Cancer pipeline drugs market are Novartis AG,  AstraZeneca Plc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Pfizer Inc, and Merck & Co Inc. Among these, Novartis AG had the most number of products under development in 2022.

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis by Key Companies

Non-Small Cell Lung Cancer Pipeline Drugs Market Analysis by Key Companies

To know more about the Non-Small Cell Lung Cancer pipeline drugs market companies, download a free report sample

Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview

Key Targets Epidermal Growth Factor Receptor, Programmed Cell Death Protein, Programmed Cell Death 1 Ligand, Hepatocyte Growth Factor Receptor, GTPase KRas, and Tubulin
Key Mechanism of Actions Epidermal Growth Factor Receptor Inhibitor, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, Hepatocyte Growth Factor Receptor Inhibitor, and GTPase KRas Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Parenteral, Intratumor, and Intravenous Drip
Key Molecule Types Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, And Fusion Protein
Key Companies Novartis AG,  AstraZeneca Plc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Pfizer Inc, and Merck & Co Inc.


  • The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer

  • The report reviews pipeline therapeutics for Non-Small Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Non-Small Cell Lung Cancer therapeutics and enlists all their major and minor projects

  • The report assesses Non-Small Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews the latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

3SBio Inc
4D Pharma Plc
A&G Pharmaceutical Inc
A. Menarini Industrie Farmaceutiche Riunite Srl
A2i Therapeutics Ltd
Aadi Bioscience Inc
Abbisko Therapeutics Co Ltd
AbbVie Inc
Abion Inc
ABL Bio Inc
ABM Therapeutics Inc
AbTis Co Ltd
AC Bioscience SA
Acepodia Inc
Achilles Therapeutics Plc
AcuityBio Corp
Adagene Suzhou Ltd
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advanced BioDesign
Advenchen Laboratories LLC
Adze Biotechnology Inc
Affimed GmbH
Agenus Inc
Agilvax Inc
AI Therapeutics Inc
Akeso Inc
Alaunos Therapeutics Inc
Alethia Biotherapeutics Inc
Alkermes Plc
Alligator Bioscience AB
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
Alpha Biopharma Ltd
Alphageneron-Pharmaceuticals Inc
Alphamab Oncology
Alpine Immune Sciences Inc
Ambrx Biopharma Inc
Amgen Inc
Aminex Therapeutics Inc
AmMax Bio Inc
Amphivena Therapeutics Inc
Anagenics Ltd
Anaveon AG
AnBogen Therapeutics
AnHeart Therapeutics Inc
Anhui Anke Biotechnology (Group) Co Ltd
Ansun Biopharma Inc
Antapodia Therapeutics Inc
Antengene Corp Ltd
Antibody Therapeutics Inc
AP Biosciences Inc
Apexigen Inc
Apollomics Inc
Applied Pharmaceutical Science Inc
Applied Research using OMIC Sciences SL
Aprea Therapeutics Inc
Aravive Inc
Arbella Therapeutics LLC
Arch Oncology Inc
Arcus Biosciences Inc
Ardan Pharma
Ariz Precision Medicine Inc
Aro Biotherapeutics Co
Arthrosi Therapeutics Inc
Arvinas Inc
Asana BioSciences LLC
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
Ascentgene Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atreca Inc
aTyr Pharma Inc
Aulos Bioscience Inc
AUM Biosciences Pte Ltd
Aurigene Discovery Technologies Ltd
Aurobindo Pharma Ltd
Avacta Life Sciences Ltd
AvenCell Europe GmbH
Avesthagen Ltd
Axelar AB
Baobab AiBIO Co Ltd
Base Therapeutics
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Anshi Biotechnology Co Ltd
Beijing Biostar Technologies Ltd
Beijing Eastern Biotech Co Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Konruns Pharmaceutical Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Pearl Biotechnology LLC
Beijing Scitech-MQ Pharmaceuticals Ltd
BerGenBio ASA
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
Better Life Pharmaceuticals Inc
BeyondSpring Inc
Bicycle Therapeutics Plc
Bika Biotechnology Guanzhou Co Ltd
Binjiang Pharma, Inc.
Bio-Path Holdings Inc
Bio-Synectics Inc
Bio-Thera Solutions Ltd
Bio4t2 LLC
BioAtla Inc
Biohaven Pharmaceutical Holding Company Ltd
BioInvent International AB
BioMarck Pharmaceuticals Ltd
Biomea Fusion Inc
BioMed Valley Discoveries Inc
BiOneCure Therapeutics Inc
BioNTech SE
Biosion Inc
Biosplice Therapeutics Inc
Biotheus Inc
Bioven Group
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
BJ Bioscience Inc
Black Diamond Therapeutics Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bolt Biotherapeutics Inc
Boston Pharmaceuticals Inc
BoYen Therapeutics Inc
BriaCell Therapeutics Corp
Bridge Biotherapeutics Inc
BridgeBio Pharma Inc
BrightGene Bio-Medical Technology Co Ltd
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calico Life Sciences LLC
Calithera Biosciences Inc
CanBas Co Ltd
Candel Therapeutics Inc
Cantargia AB
Cascade Prodrug Inc
Catalym GmbH
Cellatoz Therapeutics Inc
CellCentric Ltd
Celldex Therapeutics Inc
Cellestia Biotech AG
Celltrion Inc
Cellular Biomedicine Group Inc
Cellworks Group Inc
Celularity Inc
Centaurus Biopharma Co Ltd
Centurion BioPharma Corp
Checkpoint Therapeutics Inc
Chengdu Di'ao Pharmaceutical Group Co Ltd
Chengdu Huajian Future Science And Technology Co Ltd
Chengdu Huitai Biomedicine Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chengdu Yongkang Pharmaceutical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China Resources Pharmaceutical Group Ltd
Chinook Therapeutics Inc
Chiome Bioscience Inc
Chong Kun Dang Pharmaceutical Corporation
Chugai Pharmaceutical Co Ltd
Cipla BioTec Pvt Ltd
Cloaked Therapeutics LLC
Clonz Biotech Pvt Ltd
Clovis Oncology Inc
Co-D Therapeutics Inc
Codiak BioSciences Inc
Compass Therapeutics Inc
Compugen Ltd
Corcept Therapeutics Inc
Cortice Biosciences Inc
Corvus Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cullgen Inc
Cullinan Oncology Inc
Cureport Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
Cyclica Inc
Cyrus Therapeutics Inc
Cytocraft Bio-Tech Development Co Ltd
CytoImmune Therapeutics Inc
CytomX Therapeutics Inc
D3 Bio Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
Denovo Biopharma LLC
DexTech Medical AB
DiNonA Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Dracen Pharmaceuticals Inc
Dragonfly Therapeutics Inc
Duality Biologics (Shanghai) Co Ltd
Duo Oncology Inc
Dyadic International Inc
DynamiCure Biotechnology LLC
Eden Biologics Inc
Edison Oncology Holding Corp
eFFECTOR Therapeutics Inc
EirGenix Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Eli Lilly and Co
Elicio Therapeutics Inc
Ella Therapeutics Ltd
Elpiscience Biopharma Ltd
Elucida Oncology Inc
Enhancedbio Inc
Enliven Therapeutics Inc
Enzene Biosciences Ltd
EpicentRx Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Epygen Biotech Pvt Ltd
Erasca Inc
Esanex Inc
Etern BioPharma Co Ltd
Euclises Pharmaceuticals Inc
Eucure (Beijing) Biopharma Co Ltd
Eudendron Srl
Eureka Therapeutics Inc
Eutilex Co Ltd
Evaxion Biotech ApS
Evestra Inc
Evotec SE
Exeliom Biosciences SAS
Exelixis Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fannin Innovation Studio
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
Felicitex Therapeutics Inc
FibroStatin SL
Flame Biosciences Inc
Fochon Pharmaceutical Ltd
Foghorn Therapeutics Inc
Formosa Pharmaceuticals Inc
Foshan Rexie Biotechnology Co Ltd
Fujifilm Holdings Corp
Fulgent Pharma LLC
Future Medicine Co Ltd
G&E Herbal Biotechnology Co., Ltd.
G1 Therapeutics Inc
GAiA BioMedicine Inc
Galectin Therapeutics Inc
Galecto Inc
Galera Therapeutics Inc
Gan & Lee Pharmaceuticals Co Ltd
Gedeon Richter Plc
GeneCraft Inc
Genelux Corp
Genentech USA Inc
Geneos Therapeutics Inc
GeneQuantum Healthcare Suzhou Co Ltd
Generos Biomedical Technology (Hangzhou) Co Ltd
GeneScience Pharmaceuticals Co Ltd
Genexine Inc
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Genocea Biosciences Inc
GenoImmune Therapeutics Biotechnology Co Ltd
Genome & Co
Genor BioPharma Co Ltd
Genosco Inc
Genprex Inc
Gensun Biopharma Inc
Gilead Sciences Inc
GLG Pharma SA
GlycaNova AS
GlycoNex Inc
Glycotope GmbH
Golden Biotechnology Corp
Gradalis Inc
Grid Therapeutics LLC
Gritstone Bio Inc
GSK plc
GT Biopharma Inc
Guangdong Yinzhu Pharmaceutical Technology Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Anjie Biomedical Technology Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Bio-gene Technology Co Ltd
Guangzhou DM Intelligence Ltd
Guangzhou Doublle Bioproduct Inc
Guangzhou Sinogen Pharmaceutical Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
HaimBio Ltd
Hainan Yuekang Biological Medicine Co Ltd
Handok Inc
Hangzhou DAC Biotech Co Ltd
Hangzhou Neoantigen Therapeutics Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Harmonic Pharma
HEC Pharma Co Ltd
Hefei Hankemab Biotechnology Co Ltd
Helix BioPharma Corp
Helsinn Group
Henan Genuine Biotech Co Ltd
Henan Topfond Pharmaceutical TCM Co Ltd
Hibercell Inc
HiFiBiO Therapeutics Inc
Highlight Therapeutics SL
HitGen Inc
Hope Biosciences LLC
Horizon Therapeutics Plc
Huabo Biopharm (Shanghai) Co Ltd
Huadong Medicine Co Ltd
Huahui Anjian (Beijing) Biotechnology Co Ltd
Hualan Biological Engineering Inc
Hubei Soundny Bio-Tech Co Ltd
Humanwell Healthcare Group Co Ltd
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
iCeutica Inc
Ideaya Biosciences Inc
Idera Pharmaceuticals Inc
Ikena Oncology Inc
Imhotep Diagnostics & Therapeutics Ltd
Immuneering Corp
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneSensor Therapeutics Inc
ImmuNext Inc
Immunitas Therapeutics Inc
ImmunityBio Inc
Immunocore Holdings Plc
ImmunoGen Inc
Immunophotonics Inc
ImmunSYS Inc
Immutep Ltd
Immvira Co Ltd
Imugene Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
Inflection Biosciences Ltd
Inhibrx Inc
Inmune Bio Inc
Innate Pharma SA
Inner Mongolia Qite Biotechnology (Group) Co Ltd
InnoCare Pharma Ltd
InnoCure Therapeutics Inc
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Inspirna Inc
Instil Bio Inc
Insud Pharma
InteRNA Technologies BV
Intima Bioscience Inc
Intocell Inc
InventisBio Co Ltd
Inventiva SA
InxMed (Beijing) Co Ltd
IO Biotech Inc
Io Therapeutics Inc
iOnctura SA
Iovance Biotherapeutics Inc
Ipsirius SAS
iTeos Therapeutics Inc
Iterion Therapeutics Inc
ITM Isotope Technologies Munich SE
Ivy Life Sciences Co Ltd
J Ints Bio Co Ltd
Jacobio Pharmaceuticals Group Co Ltd
Janux Therapeutics Inc
Jazz Pharmaceuticals Plc
Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Maidu Drug Research and Development Co Ltd
Jiangsu Suzhong Pharmaceutical Group Co Ltd
Jiangsu Wuzhong Pharmaceutical Group Co Ltd
Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd
Jiangxi Jemincare Group Co Ltd
Jiangxi Qingfeng Pharmaceutical Co Ltd
Jing Medicine Technology Shanghai Ltd
Johnson & Johnson
Jounce Therapeutics Inc
JS InnoPharm (Shanghai) Ltd
JSK Therapeutics Inc
JSR Life Sciences LLC
Jubilant Therapeutics Inc
Kadmon Holdings Inc
KAHR medical Ltd
Kairos Pharma Ltd
Kanaph Therapeutics Inc
Karyo Biologics LLC
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Kineta Inc
Kinnate Biopharma Inc
Kirilys Therapeutics Inc
Kiromic BioPharma Inc
Kronos Bio Inc
Kura Oncology Inc
Kymab Ltd
Kymera Therapeutics Inc
L&L Biopharma Co Ltd
L.E.A.F. Pharmaceuticals LLC
LaNova Medicines Ltd
Lantern Pharma Inc
LATITUDE Pharmaceuticals Inc
Le Sun Pharmaceuticals Ltd
Legend Biotech Corp
LegoChem Biosciences Inc
Lepu Biopharma Co Ltd
Les Laboratoires Servier SAS
Levim Biotech LLP
LIfT BioSciences Ltd
Light Chain Bioscience
Lime Therapeutics Inc
Lineage Cell Therapeutics Inc
Linnaeus Therapeutics Inc
Lipomedics Ltd
LipoSeuticals Inc
Livzon Pharmaceutical Group Co Ltd
Lixte Biotechnology Holdings Inc
Lotus Pharmaceutical Co Ltd
Loxo Oncology Inc
Lupin Ltd
Luye Pharma Group Ltd
Lycera Corp
Lyell Immunopharma Inc
Lyvgen Biopharma Ltd
Mabpharm Ltd
Mabwell Shanghai Bioscience Co Ltd
Machavert Pharmaceuticals LLC
MacroGenics Inc
MAIA Biotechnology Inc
Marengo Therapeutics Inc
Maverick Therapeutics Inc
MedAbome Inc
Medical Guidance Systems LLC
Medicenna Therapeutics Corp
MedPacto Inc
Memgen Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Merus NV
Meryx Inc
Metaclipse Therapeutics Corp
METiS Therapeutics Inc
Microbio Co Ltd
Microbiotica Ltd
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
MiNK Therapeutics Inc
Mirati Therapeutics Inc
Moderna Inc
Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Targeting Technologies Inc
Molecular Templates Inc
Monte Rosa Therapeutics Inc
Morvus Technology Ltd
Multitude therapeutics Inc
Mycenax Biotech Inc
MyeloRx LLC
Nalo Therapeutics Inc
Nanjing CART Medical Technology Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanobiotix SA
Nanology LLC
NantBioScience Inc
Natsar Pharmaceuticals Inc
Navire Pharma Inc
Navrogen Inc
Nektar Therapeutics
Nemucore Medical Innovations Inc
NeoTX Therapeutics Ltd
Netris Pharma SAS
Neumedicines Inc
New Beta Innovation Ltd
Newish Technology Beijing Co Ltd
NextCure Inc
NGM Biopharmaceuticals Inc
NH TherAguix SAS
NightHawk Biosciences Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Nitto BioPharma Inc
NKGen Biotech Inc
Nouscom AG
Novartis AG
Noxopharm Ltd
NuCana Plc
Numab Therapeutics AG
Nurix Therapeutics Inc
Nuvalent Inc
OBI Pharma Inc
OBiO Technology (Shanghai) Corp Ltd
Obsidian Therapeutics Inc
Ocean Biomedical Inc
Ocellaris Pharma Inc
Ocuphire Pharma Inc
Omega Therapeutics Inc
Oncobix Co Ltd
OncoC4 Inc
Oncolys BioPharma Inc
Oncomatryx Biopharma SL
Onconic Therapeutics Co Ltd
Onconova Therapeutics Inc
OncoResponse Inc
Oncorus Inc
OncoTrap Inc
OncXerna Therapeutics Inc
Oneness Biotech Co Ltd
ONK Therapeutics Ltd
Ono Pharmaceutical Co Ltd
Onxeo SA
Ophelos Therapeutics Pty Ltd
Orano Med LLC
Origincell Technology Group Co Ltd
Oryx GmbH & Co KG
OSE Immunotherapeutics SA
OtiTopic Inc
Otsuka Pharmaceutical Co Ltd
Outlook Therapeutics Inc
Oxford BioTherapeutics Ltd
Oxford Vacmedix UK Ltd
P&PMed Shanghai Biotechnology Co Ltd
Pacylex Pharmaceuticals Inc
Palleon Pharmaceuticals Inc
Palo BioFarma SL
Panbela Therapeutics Inc
Partner Therapeutics Inc
PDC Line Pharma SAS
PDS Biotechnology Corp
PeLeMed Co Ltd
Penrose Therapeutix LLC
Peptomyc SL
Perturba Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
PHusis Therapeutics Inc
Pinetree Therapeutics Inc
PlantForm Corp
Plexium Inc
Plus Therapeutics Inc
PlusVitech SL
PNB Vesper Life Science Pvt Ltd
Polaris Pharmaceuticals Inc
Portage Biotech Inc
Poseida Therapeutics Inc
Potenza Therapeutics Inc
Precision Biologics Inc
Precision Biotechnology Co Ltd
Prelude Therapeutics Inc
Prestige BioPharma Ltd
Primevax Immuno Oncology Inc
ProfoundBio Suzhou Co Ltd
Promontory Therapeutics Inc
Propanc Biopharma Inc
Protgen Ltd
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Pure Biologics SA
Purple Biotech Ltd
Pyxis Oncology Inc
Qilu Pharmaceutical Co Ltd
Qingdao Sino-Cell Biomedicine Co Ltd
Qu Biologics Inc
Qurient Co Ltd
Radiopharm Theranostics Ltd
Rapa Therapeutics LLC
RAPT Therapeutics Inc
RaQualia Pharma Inc
Reata Pharmaceuticals Inc
Recombio SL
Recursion Pharmaceuticals Inc
RedCloud Bio Inc
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
ReguGene Co Ltd
RemeGen Co Ltd
Repare Therapeutics Inc
Repertoire Immune Medicines Inc
Replimune Ltd
Reven Holdings Inc
Revolution Medicines Inc
Rhizen Pharmaceuticals SA
Roivant Sciences Ltd
Rophibio Inc
RS Research
Sagimet Biosciences Inc
Salubris Biotherapeutics Inc
Scancell Holdings Plc
Scholar Rock Inc
ScinoPharm Taiwan Ltd
Scorpion Therapeutics Inc
Seagen Inc
SELLAS Life Sciences Group Inc
Sensei Biotherapeutics Inc
Sentinel Oncology Ltd
Seven and Eight Biopharmaceuticals Corp
Shandong Boan Biotechnology Co Ltd
Shandong Buchang Pharmaceutical Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shanghai Affinity Biomedical Technology Co Ltd
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Gefeimu Biomedical Technology Co Ltd
Shanghai Gencells Therapeutics Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Houchao Biotechnology Co Ltd
Shanghai Hui Dong Biotechnology Co Ltd
Shanghai Institute of Biological Products Co Ltd
Shanghai Jiyu Pharmaceutical Technology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Yidian Pharmaceutical Technology Development Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenogen Pharma Group Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Forward Pharmaceutical Co Ltd
Shenzhen Neptunus Institute of Pharmaceutical Technology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Targetrx Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shionogi & Co Ltd
Shouyao Holding Co Ltd
Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Signablok Inc
SignalChem Lifesciences Corp
SignPath Pharma Inc
Sihuan Pharmaceutical Holdings Group Ltd
Simcere Pharmaceutical Group Ltd
Simcha Therapeutics Inc
Singh Biotechnology LLC
Sino Biopharmaceutical Ltd
SinoCelltech Group Ltd
Sirnaomics Ltd
SiVEC Biotechnologies LLC
SK Life Science Inc
Smerud Medical Research International AS
Sonnet BioTherapeutics Holdings Inc
Sonoval LLC
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Sosei Group Corp
SOTIO Biotech AS
Specific Biologics Inc
Sphaera Pharma Pte Ltd
SpringWorks Therapeutics Inc
ST Pharm Co Ltd
Starpharma Holdings Ltd
STAT3 Therapeutics Inc
Statera Biopharma Inc
Stcube Inc
Stemirna Therapeutics Ltd
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Oncology, Inc
Sumitomo Pharma Co Ltd
Shenghe (China) Biopharmaceutical Co Ltd
Suntec Medical (Taiwan) Inc
SupremeCure Pharma Inc
Surface Oncology Inc
Sutro Biopharma Inc
SuviCa Inc
Suzhou BlueHorse Therapeutics Co Ltd
Suzhou Dingfu Target Biotechnology Co Ltd
Suzhou GenHouse Pharmaceutical Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Suzhou Medilink Therapeutics Ltd
Suzhou Neupharma Co Ltd
Suzhou Shengdia Biomedical Co Ltd
Suzhou Stainwei Biotech Inc
Suzhou Teligene Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Suzhou Zerun New Drug Research and Development Co Ltd
Symphogen A/S
Synactix Pharmaceuticals Inc
Syncromune Inc
SynDevRx Inc
Synermore Biologics Co Ltd
Synthekine Inc
Syntrix Pharmaceuticals
Systimmune Inc
T-Cure Bioscience Inc
Tactical Therapeutics Inc
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Taizhou Maibotek Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Tango Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd
Tavotek Biotherapeutics
TCR2 Therapeutics Inc
Teclison Ltd
Tempest Therapeutics Inc
Teon Therapeutics Inc
Tetranov International Inc
Tevogen Bio Inc
Therabest Co Ltd
Theralase Technologies Inc
Therapex Corp
Theseus Pharmaceuticals Inc
Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tianjin Hengjia Biotechnology Development Co Ltd
TILT Biotherapeutics Ltd
Tiziana Life Sciences Plc
Tizona Therapeutics Inc
Tmunity Therapeutics Inc
TOLREMO Therapeutics AG
TOT Biopharm Co Ltd
TRACON Pharmaceuticals Inc
Transcenta Holding Ltd
Treadwell Therapeutics Inc
Triumvira Immunologics Inc
TScan Therapeutics Inc
Turning Point Therapeutics Inc
Turnstone Biologics Inc
Tvardi Therapeutics Inc
Twinpigbiolab Co Ltd
TYK Medicines Inc
Tyme Inc
Tyra Biosciences Inc
UbiVac Inc
Ultimovacs AS
United BioPharma Inc
United Immunity Co Ltd
Vaccinex Inc
Vaccitech Plc
Valo Therapeutics Oy
VasGene Therapeutics Inc
Vault Pharma Inc
Vaximm AG
Vaxon Biotech
Venus Remedies Ltd
Verastem Inc
VITRAC Therapeutics LLC
Vivacitas Oncology Inc
Voronoi Group
VREX Therapeutics Inc
Vyriad Inc
Wayshine Biopharma Inc
WellMarker Bio Co Ltd
Western Oncolytics Ltd (Inactive)
Wigen Biomedicine Technology (Shanghai) Co Ltd
WindMIL Therapeutics Inc
Wuxi Shuangliang Biotechnology Co Ltd
Xbiome Co Ltd
Xbrane Biopharma AB
Xcovery Holding Co LLC
Xencor Inc
Xiangxue Life Sciences
Xiconic Pharmaceuticals LLC
Xilio Therapeutics Inc
XuanZhu Biological Technology Co Ltd
Xynomic Pharmaceuticals Holdings Inc
Y-Biologics Inc
Yangtze River Pharmaceutical Group
Yooyoung Pharm Co Ltd
Yuhan Corp
Zelluna Immunotherapy AS
Zentalis Pharmaceuticals Inc
Zhejiang Bossan Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Jianfeng Group Company Ltd
Zhejiang Landun Pharmaceutical Co Ltd
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhejiang Yangshengtang Biotech Co Ltd
Zhuhai Beihai Biotech Co Ltd
Zhuhai GRIT biotechnology Inc
Zucero Therapeutics Ltd
Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Non-Small Cell Lung Cancer – Overview

Non-Small Cell Lung Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Non-Small Cell Lung Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non-Small Cell Lung Cancer – Companies Involved in Therapeutics Development

Non-Small Cell Lung Cancer – Drug Profiles

Non-Small Cell Lung Cancer – Dormant Projects

Non-Small Cell Lung Cancer – Discontinued Products

Non-Small Cell Lung Cancer – Product Development Milestones

Featured News & Press Releases




Secondary Research

Primary Research

Expert Panel Validation

Contact Us


Frequently asked questions

Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.